Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S18986 in Mild Cognitive Impairment
NCT00202540Phase 2Terminated
- Sponsor
- Servier
- Start
- Jun 2005
- Primary completion
- Mar 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of s18986 in Mild Cognitive Impairment (MCI), sponsored by Servier. Primary endpoint: Episodic memory performance at 12 months. Started Jun 2005; status: terminated.
02
Drugs
s18986
03
Conditions
Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on NCT00202540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00202540.